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The search for effective Hepatitis C antiviral therapies has recently focused on host sterol
metabolism and protein prenylation pathways that indirectly affect viral replication. However,
inhibitionofthesterolpathwaywithstatindrugshasnotyieldedconsistentresultsinpatients.Here,
we present a combination chemical genetic study to explore how the sterol and protein prenylation
pathways work together to affect hepatitis C viral replication in a replicon assay. In addition to
ﬁnding novel targets affectingviralreplication,ourdata suggest thattheviralreplication is strongly
affected by sterol pathway regulation. There is a marked transition from antagonistic to synergistic
antiviraleffectsasthecombinationtargetsshiftdownstreamalongthesterolpathway.Wealsoshow
how pathway regulation frustrates potential hepatitis C therapies based on the sterol pathway, and
revealnovelsynergies that selectively inhibithepatitis C replication overhost toxicity. In particular,
combinations targeting the downstream sterol pathway enzymes produced robust and selective
synergistic inhibition of hepatitis C replication. Our ﬁndings show how combination chemical
genetics can reveal critical pathway connections relevant to viral replication, and can identify
potential treatments with an increased therapeutic window.
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Introduction
The hepatitis C virus (HCV) is an enveloped single-stranded
positive-sense RNA virus in the family ﬂaviviridae (Lindenbach
andRice,2001).TheB9.6kbgenomeistranslatedintoasingle
polyprotein that is subsequently processed into at least 10
structural and nonstructural proteins that are necessary for
replication of viral RNA and assembly of new virions
(Lindenbach and Rice, 2001). Historically, the study of the
HCV life cycle has been difﬁcult, given the inability of HCV to
replicate in vitro in tissue-cultured cells (Lindenbach and Rice,
2005). However, the development of full length and sub-
genomic replicons, which express HCV proteins sufﬁcient for
replication of viral RNA in hepatoma (Huh-7) cells,has greatly
improved our understanding of HCV biology and virus–host
interactions (Lohmann et al, 1999; Blight et al, 2000).
Acriticalvirus–hostinteractionrequiredforHCVreplication
is the membrane-associated complex composed of viral and
host proteins and altered cellular membranes, designated the
membranous web (Egger et al, 2002; Gosert et al, 2003). This
association with host membranes has proven to be a useful
strategyforHCVasmembranescanserveasaﬁxedobjectfrom
which viral proteins can be tethered. FBL2 has been identiﬁed
as a 50kDa geranylgeranylated host protein that is necessary
for localization of the HCV replication complex through its
close association with the HCV protein NS5A and is critical for
HCV replication (Wang et al, 2005). The extent of FBL2
geranylgeranylation is known to impact HCV replication. For
example, inhibition of the protein geranylgeranyl transferase I
(PGGT), an enzyme that transfers geranylgeranyl pyrophos-
phate (GGPP) to cellular proteins for the purpose of
membrane anchoring, negatively impacts HCV replication
(Ye et al, 2003). Conversely, chemical agents that increase
intracellular GGPP concentrations promote viral replication
(Kapadia and Chisari, 2005). Given the importance of
host membranes to HCV replication, it is not surprising
that metabolites from these pathways impact HCV RNA
replication.
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videsthebasisforcurrentcandidatetherapiesfortreatingHCV
infections using statin drugs.Host cell membranecomposition
can be directly modiﬁed by products of the sterol pathway,
which is vital for synthesis of cholesterol and isoprenoid
intermediates, and the fatty acid biosynthetic pathway (Gold-
stein and Brown, 1990). Chemical inhibition of enzymes in
either of these pathways has been shown to impact viral
replication, both positively and negatively (Su et al, 2002; Ye
et al, 2003; Kapadia and Chisari, 2005; Sagan et al, 2006;
Amemiya et al, 2008). For example, statin compounds inhibit
3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR),
the rate-limiting enzyme in the sterol pathway (Goldstein
and Brown, 1990), and have been suggested to inhibit
HCV replication through ultimately reducing the cellular
pool of GGPP (Ye et al, 2003; Kapadia and Chisari, 2005;
Ikeda et al, 2006).
However, clinical doses of statins currently used to treat
hypercholesterolemia are not high enough to inhibit the
synthesis of geranyl lipids. The use of statins for the treatment
of HCV is likely to be further complicated by the reported
compensatory increase in HMGCR expression in vitro and
in vivo (Stone et al, 1989; Cohen et al, 1993) in response to
treatment. The recent ﬁnding that HCV RNA replication
increases with ﬂuvastatin treatment in HIV/HCV coinfected
patients (Milazzo et al, 2009) is consistent with an increase in
HMGCR expression. Enzymes in the sterol pathway are
regulated on a transcriptional level by sterol regulatory
element-binding proteins (SREBPs), speciﬁcally SREBP-2,
which is an ER membrane-bound transcription factor (Hua
et al, 1993; Brown and Goldstein, 1997). When cholesterol
stores in cells are depleted, SREBP-2 is escorted from the ER to
the Golgi complex by SREBP cleavage-activating protein, a
sterol-sensing escort protein (Hua et al, 1996; Brown and
Goldstein, 1999). SREBP-2 is subsequently cleaved by the
Golgi-localized proteases S1P and S2P, thereby releasing the
N-terminal basic helix-loop-helix domain, which migrates to
the nucleus and activates transcription of genes in the sterol
pathway that contain sterol response elements in their
enhancers (Smith et al, 1988, 1990; Sakai et al, 1996; Brown
and Goldstein, 1999). Well-characterized target genes include
HMGCR, HMG-CoA synthase, farnesyl pyrophosphate (FPP)
synthase, squalene synthase (SQLS) and the LDL receptor
(Horton et al, 2002). The requirement of additional down-
stream sterol pathway metabolites for HCVreplication has not
been completely elucidated.
Chemical genetics is an effective way of determining drug
mechanisms (Stockwell, 2004) where, in the simplest form,
single chemical perturbations can elucidate which compo-
nentsinasystemareessentialforagivenphenotype.However,
functional connections between system components are best
identiﬁed either by direct interaction data or through measur-
ing combination effects (Boone et al, 2007). One approachthat
has been successful is the use of chemical perturbagens
applied in combination (Leha ´r et al, 2007, 2008). For such
combination chemical genetic studies, the interaction needs to
becomparedtotheindividualsingle-agenteffectstodetermine
whether there is ‘synergy,’ where the agents cooperate toward
a phenotype, or ‘antagonism,’ where they impede each other’s
activity (Greco et al, 1995). Thus,themechanistic focus can be
shifted from the individual targets to the interactions between
them.
Here, we present a chemical genetic screen undertaken to
further understand the impact of the sterol pathway and its
regulation on HCV replicon replication using a combination
high-throughput screening platform (cHTS) (Borisy et al,
2003). Using this approach, we identiﬁed several effective
antiviral targets including SREBP-2 as well as targets down-
streamofHMGCRinthesterolpathwaysuchasoxidosqualene
cyclase (OSC) or lanosterol demethylase. Of note, combina-
tions between probes targeting enzymes downstream of OSC
produced robust synergies with each other or with a PGGT
inhibitor. Furthermore, our data suggest that inhibition of the
sterol pathway without inhibition of regulatory feedback
mechanisms ultimately results in an increase in replicon
replication. Consequently, combinations of inhibitors of
targets upstream of OSC appeared antagonistic with dominant
epistatic effects over inhibitors of downstream targets.
Results
To elucidate the detailed mechanism connecting the sterol
biosynthesis pathway to HCV replication, we conducted a
chemical genetic screen using our cHTS platform (Borisy et al,
2003; Leha ´r et al, 2009). We selected 16 chemical probes that
are known to modulate the activity of target enzymes relating
to the sterol biosynthesis pathway (Figure 1; Table I). These
chemical probes provide dense sampling of the sterol pathway
Figure 1 Chemical probes used to modulate targets relating to the sterol
biosynthesis pathway, and also to target a proviral pathway mediated by host
protein prenylation. The schematic diagram shows the sterol biosynthesis
pathway, showing where it interacts with protein prenylation through
geranylgeranyl transferase (PGGT). Each chemical probe is shown with a
markerconnectingittoanenzymatictarget,eitherasaninhibitor/antagonistoras
an agonist.
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study involved comprehensively testing all the probes as
single agents and in pairwise combinations, using assays that
model both replicon replication and host viability. A compre-
hensive diagram of the cholesterol biosynthesis pathway is
shown in Supplementary Figure S1.
Inhibition of the sterol pathway can inhibit
or stimulate replicon replication
To conﬁrm and extend previous studies that showed modula-
tion of HCV replication through the sterol pathway, we added
chemical probes of the sterol pathway to Huh-luc/neo-ETcells
expressing an HCV genotype 1b subgenomic replicon and a
luciferase reporter. The resulting impact on luciferase expres-
sion, a measure of replicon replication, was determined for all
singleagentsaftera48hincubationandthesingle-agentdose–
response curves are reported in Figure 2A. A host proliferation
counterscreen measuring cellular ATP levels after a 48h
incubation with compound was assessed in parallel
(Figure 2A) in the parental Huh-7 cell line not containing a
replicon and the data were used to evaluate the selectivity of
each probe. We previously determined an acceptable selectiv-
ity index by microscopic visualization of cells treated with
compounds. We found that Huh-7 cells could tolerate a
measureable reduction in ATP levels of up to B30–40%
without any visual impact on cell ﬁtness (data not shown). All
of the compounds tested produced either increases (proviral)
or decreases (antiviral) in replicon replication. Measurements
were obtained using serially diluted dose series (by a dilution
factor of two), with at least four-fold replicates, and the
inhibitions and standard error estimates were determined by
calculating the mean change in response relative to untreated
cell cultures on each experimental plate (see Materials and
methods).
Severalchemical probeswith selectivesingle-agentantiviral
activity were identiﬁed. Colestolone, the OSC inhibitors
Ro48-8071 and U18666A, as well as amorolﬁne and the related
compound fenpropimorph, all inhibited HCV replication with
marginalimpactonhostcellATPlevels.Colestoloneisapotent
inhibitor of cholesterol synthesis through many different
mechanisms. Colestolone can be metabolized by the cell into
polar sterols, which are known to inhibit HMGCR enzymatic
activity (Swaminathan et al, 1995). In addition, colestolone
inhibits SREBP2 activation (Schmidt et al, 2006), which
ultimately reduces transcription of HMGCR and HMGCS, as
well as many other SREBP2-dependent genes. Both U18666A
and Ro48-8071 were highly potent and selective HCV replica-
tion inhibitors with inhibitory concentration at 50% effect
(IC50) values in the nM range. In the data presented in
Figure 2A, Ro48-8071 treatment results in B50% inhibition of
viral replication at the highest concentration shown in the
ﬁgure. In other experiments not presented here, we observed
up to 100% inhibition at higher concentrations. Although
amorolﬁneand fenpropimorph mainlyaffect sterol isomerases
and reductases in plants and fungi, their main target in
mammaliancellsappearstobethedemethylationoflanosterol
(Corio-Costet et al, 1988).
Many of our chemical probes, speciﬁcally SR-12813,
farnesol and squalestatin, strongly promoted replicon replica-
tion. The actions of both farnesol and squalestatin ultimately
result in an increase in the cellular pool of GGPP, which has
been shown earlier to increase HCVreplication (Ye et al, 2003;
Kapadia and Chisari, 2005; Wang et al, 2005). SR-12813 is a
reported HMGCR degradation enhancer (Berkhout et al, 1996)
and was expected to inhibit HCV replication through a
reduction in the cellular pool of GGPP. The proviral activity
of this compound is not understood.
The selectivity of the remaining chemical probes tested in
our screen is less clear, given the host cell ATP depletion
observed at most antiviral concentrations. AY-9944 and
triparanol, inhibitors of the downstream targets D7- and D24-
reductase, respectively, exhibited marginal selectivity despite
previous reports that inhibition of these sterol reductases is
compatible with cell proliferation (Rujanavech and Silbert,
1986; Fernandez et al, 2005). Previous reports have suggested
that viral replication is impacted by the products of the fatty
acid biosynthesis pathway (Kapadia and Chisari, 2005;
Amemiya et al, 2008). We found that the chemical probe
Table I Chemical probes that inhibit enzymes within and outside the sterol pathway
Drug name CAS number Conc. range (mM) Target function Target protein
TOFA 54857-86-2 0.02–26.5 Fatty acid synthesis Acetyl-CoA carboxylase (ACoAC)
Colestolone 50673-97-7 0.03–29.2 Cholesterol metabolism Sterol regulatory element binding protein (SREBP)
SR 12813 126411-39-0 0.03–29.4 Sterol synthesis 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)
Simvastatin 79902-63-9 0.03–29.4 Sterol synthesis 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)
Alendronate 121268-17-5 0.014–29.4 Sterol synthesis Farnesyl pyrophosphate synthase (FPPS)
Farnesol 4602-84-0 0.03–29.4 Sterol synthesis Squalene synthase (SQLS)
Squalestatin 142561-96-4 0.03–29.4 Sterol synthesis Squalene synthase (SQLS)
Clomiphene 50-41-9 0.03–29.4 Sterol synthesis Squalene epoxidase (SQLE)
Ro 48-8071 189197-69-1 0.03–29.4 Sterol synthesis Oxidosqualene cyclase (OSC)
U18666A 3039-71-2 0.0007–10.5 Sterol synthesis Oxidosqualene cyclase (OSC)
Terconazole 67915-31-5 0.03–29.4 Sterol synthesis Lanosterol C14-demethylase (C14dM)
Amorolﬁne 78613-35-1 0.03–29.4 Sterol synthesis Lanosterol C14-demethylase (C14dM)
a
Fenpropimorph 67564-91-4 0.03–29.4 Sterol synthesis Lanosterol C14-demethylase (C14dM)
a
AY-9944 366-93-8 0.1–13.4 Sterol synthesis Sterol delta-7 and delta-14 reductase (d7/d14R)
Triparanol 78-41-1 0.03–29.4 Sterol synthesis Sterol delta-24 reductase (d24R)
GGTI-286 171744-11-9 0.07–17.9 Protein prenylation Protein geranylgeranyl transferase I (PGGT)
aTarget sterol delta-14 reductase and delta-8, delta-7 isomerase (C14d8) in plants and fungi.
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resulted in a modest depletion of ATP at most antiviral
concentrations, making it difﬁcult to determine whether the
antiviral activity is speciﬁc or because of host toxicity. As
ACoAC catalyzes the committed step in fatty acid synthesis,
the resulting host toxicity is to be expected.
It has also been reported that statins inhibit HCVreplication
through a reduction in cellular GGPP levels (Ye et al, 2003;
Kapadia and Chisari, 2005; Ikeda et al, 2006). However, in this
studywefoundthatallantiviralconcentrationsofsimvastatin,
in addition to many other statins we tested (data not shown),
correlate with a reduction in host cell ATP levels after 48h of
treatment. Thus, there is a concern that some of the antiviral
activity of statins may be nonspeciﬁc. Moreover, at statin
concentrations not associated with ATP depletion, we con-
sistently observed a proviral effect that appeared more robust
for ﬂuvastatin than for simvastatin (data not shown). Despite
the questionable selectivity of statins in our screen,
the antiviral activity of GGTI-286, an inhibitor of protein
prenylation by PGGT that has been shown earlier to inhibit
HCV replication, conﬁrmed the reported importance of
geranylgeranylation to HCV replicon replication (Ye et al,
Figure 2 Single-agent activity for the chemical probes in this study. (A) In each panel we show the response curves for both the viral replicon and host viability assays
after 48htreatment with serialtwo-fold dilutions of compounds, withreference lines at 0and 50% inhibition.IC50 values are given for each probe. Data represent means
from at least three biological replicates of each drug at each concentration tested. Standard errors, estimated from the median absolute deviation (see Materials and
methods), ranged between 3 and 20% at each tested dose, with the largest errors occurring where the response transitioned from inactive to inhibitory.( B) Effect on
HCV protein synthesis by treatment of replicon cells for 96h with the chemical probes used in this study. Protein bands from two western blots were quantiﬁed using
densitometry. Expressed levels of HCV proteins NS3 and NS5A are shown as ratios normalized to GAPDH (see Materials and methods). Each blot is a representative
chosen from three separate experiments.
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terconazole were also found to reduce host cell ATP levels to
a great enough extent that the antiviral activity of these
compounds cannot entirely be disassociated from their impact
on host cell proliferation.
Given our use of luciferase activity as a model for HCV
replication, we sought to validate the luciferase assay results
by evaluating the impact of our chemical probes on HCV
protein expression levels (Figure 2B). Chemical probes were
added to Huh-luc/neo-ETcells as described in ‘Materials and
methods’ at concentrations chosen for an absence of appreci-
able impact on host cell ATP levels to avoid nonspeciﬁc
antiviral effects. In several cases, low doses of each compound
were used, which necessitated a 96h incubation in the
presence of each probe to observe any impact on the
expression of viral proteins NS3 and NS5A. These data
conﬁrm the antiviral activity of the OSC inhibitors Ro48-8071
and U18666A, colestolone, amorolﬁne, fenpropimorph and
GGTI-286 as well as the proviral consequence of treating
replicon cells with SR-12813 and farnesol. Squalestatin
resulted in a greater increase in NS5A than in NS3 and was
less proviral at the concentration chosen than in the luciferase
assay. Of note, we consistently observed a greater level of
enhancement with NS5A over NS3, which may be a result of
the individual protein half-lives in the host cell. Chemical
probes with questionable activity such as clomiphene,
terconazole, AY-9944 and triparanol all appear to inhibit
HCV protein levels at the nontoxic concentrations chosen
without signiﬁcant impact on GAPDH protein levels. Treat-
ment of cells with simvastatin did not inhibit viral protein
levels, an observation that is consistent with nontoxic
concentrations in our luciferase assay data. These western
blot results validate our luciferase assay-based screening
approach.
Taken together, our data conﬁrm the importance of
geranylgeranylation to HCV replication and suggest that
targeting SREBP-2 activation or select downstream sterol
pathway enzymes such as OSC or lanosterol demethylase
can reduce HCV replication. We therefore sought to identify
synergistic combinations of inhibitors with the potential for
greater control of HCVreplication and to better understand the
impact of sterol pathway regulation on replicon replication
using our cHTS platform.
cHTS of the sterol pathway
After determining single-agent activities for all the chemical
agents tested in this study, we designed dose-matrix experi-
ments with concentrations centered around each drug’s IC50
when possible. To evaluate the synergistic activity of com-
pounds in combination, we compared the observed activity
across each drug combination inhibition response surface to a
superposition of effect (SPE) model that is derived from the
single-agent activity curves (see Materials and methods).
Unlike the standard reference models for combination effects
(Greco et al, 1995) the SPE model smoothly interpolates
betweentheactivitiesofbothinhibitoryandstimulatorysingle
agents, highlighting as synergies or antagonisms antiviral
responses that fall above or below the SPE expectation. An
overviewof thereplicon responses and thecorresponding host
combination activity is presented in Figure 3. The dose-matrix
response surfaces for all the compound crosses performed in
the HCV replicon assay and Huh-7 host cells are shown in
Supplementary Figures S2 and S3.
In the host viability assay, many combinations are close to
this SPE expectation, indicating the SPE model represents
typical combination effects. The exceptions are the antiproli-
feration synergies between clomiphene and non-sterol targets,
and to a lesser extent, its interactions with terconazole and
triparanol, both of which showed additional antiproliferation
synergies. There is also a curious antiproliferation antagonism
between alendronate and probes targeting upstream enzymes.
Both clomiphene and alendronate are used clinically for
activities not related to the sterol pathway, which suggests
these effects may be nonspeciﬁc. Host interactions
are associated with the toxicity of particular compounds,
and do not show pathway-dependent patterns similar to those
in the antiviral screen, suggesting the antiviral interactions
are not the result of a toxicity-dependent experimental artifact
in most cases.
In the HCV replicon assay, however, strong mechanism-
dependent patterns emerged, which are highlighted in
Figure 4. In many cases, chemical combinations elicited
Bateson-type epistatic responses, where one chemical agent’s
response predominates over the effect of the other chemical
agent (Boone et al, 2007). Combinations targeting enzymes
upstream of squalene epoxidase (SQLE) at the top of the sterol
pathway elicited responses epistatic to the effect of targeting
enzymes downstream of SQLE (Figure 4A). This was
especially notable for combinations including simvastatin
and either U18666A or squalestatin, and for squalestatin in
combination with Ro48-8071. Treatment with squalestatin
prevents the SQLS substrate, FPP from being further metabo-
lized by the sterol pathway. As FPP concentrations increase,
the metabolite can be shunted away from the sterol pathway
toward farnesylation and GGPP synthetic pathways, resulting
in an increase in host protein geranylgeranylation, including
FBL2, and consequently replicon replication. This increase in
replicon replication explains the source of the observed
epistasis over Ro48-8071 treatment. However, less clearly
understood are the epistatic effects observed between simvas-
tatin and either squalestatin or U18666A. In these two
conﬂicting examples, simvastatin is observed in one case to
antagonize the proviral effect of squalestatin treatment and in
another to antagonize the antiviral effect of U18666A.
Conﬁrmation of simvastatin’s epistasis over U18666A was
provided by western blot analysis (Figure 5A). The concentra-
tion of each compound was selected for an absence of impact
on host proliferation. The results suggest that the observed
contradictory effect of simvastatin is not an artifact. It is likely
that severalsimultaneous and competingprocessesgovernthe
outcome for these combinations, including HMGCR protein
inhibition, unspeciﬁc cytotoxicity as measured by ATP
depletion and HMGCR transcriptional regulation.
Combinations targeting the downstream end of the pathway
led to inhibitory synergy in both the replicon and host viability
assays, especially when both agents were downstream of OSC.
In the lower part of the sterol pathway there exist parallel
routes to the synthesis of cholesterol. Consequently, inhibition
of one branch of sterol synthesis does not necessarily prevent
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every case. Figure 4B highlights examples of antiviral synergy
resulting from treatment of cells with an OSC inhibitor in
combination with an inhibitor of either an enzyme upstream
or downstream of OSC. A combination of terconazole and
U18666A is synergistic without similar combination effects in
the host proliferation screen. Likewise, clomiphene was also
synergistic when added to replicon cells in combination with
U18666A. One of the greatest synergies observed in the
downstream sterol pathway is a combination of amorolﬁne
and AY 9944, suggesting that there is value in developing
combinations of drugs that target enzymes in the sterol
pathway, which are downstream of HMGCR.
Interactions with the protein prenylation pathway also
showed strong mechanisticpatterns (Figure4C).GGTI-286isa
peptidomimetic compound resembling the CAAX domain of a
protein to be geranylgeranylated and is a competitive inhibitor
of protein geranylgeranylation. Most combinations of GGTI-
286 with agents that target the pathway upstream of SQLE are
consistent with SPE. For example, simvastatin impedes the
antiviral effect of GGTI-286 at low concentrations but that
antagonism is balanced by comparable synergy at higher
concentrations. At the low simvastatin concentrations, it is
possible that a compensatory increase in HMGCR expression
leads to increased cellular levels of GGPP. Under normal
conditions, GGPP binding to PGGT displaces a geranylger-
anylated protein from the enzyme to recycle the catalytic
pocket (Taylor et al, 2003). An increase in free GGPP could
result in an increase in PGGT enzymatic turnover and
decreased GGTI-286 efﬁcacy, as is observed. The antiviral
synergy observed at the higher inhibitor concentrations is
likely nonspeciﬁc as synergy was also observed in the host
viability assay. Further downstream, however, a competitive
interaction was observed between GGTI-286 and squalestatin,
Figure 3 Overview of the HCV replicon and host responses showing the observed combination activity. Dose-matrix data were obtained by testing all pairs of serially
diluted (two-fold) concentrations for each pair of probes (Supplementary Table S1). Activity values A¼ log10(T/U) were calculated at each dosing point by comparing
the treated T viability level to untreated values V obtained from B20 vehicle-treated wells arranged on each experimental plate (see Materials and methods). Dose
matrices were obtained with at least four replicates. Uncertainties on the activity, estimated from the scatter between replicates (see Materials and methods), were
typicallyB0.1,averagedacrosseachdosingmatrix(SupplementaryTableS1).Foreachpairofchemicalprobes,thelevelofinteractionobservedbetweentheagentsis
shown as a circle scaled to the synergy score S, relative to a ‘superposed effect’ (SPE) model of non-interaction (see Materials and methods). The SPE model
interpolates smoothly between single-agent effects that can be either inhibitory or stimulatory. Positive S (solid or red circles) correspond to synergistic interaction when
both agents are inhibitory, and to the dominance at high combined concentrations of the inhibitory agent when one of the agents has stimulatory activity (e.g.
squalestatin). Negative S corresponded to antagonism between inhibitors or dominance of the stimulatory agent. A synergy score of 1 means that there was a volume
of 1 between the observed response and the SPE model surface, integrated over the dose matrix. The scale of these scores depends on the number and densityo f
concentration points tested, and thus is mainly useful for comparisons between combinations, rather than providing an absolute reference level for synergy. Given that
the individual activity measurements tendedto havestandard errorsof saB0.1, onlysynergy scores outside of±3can be considered signiﬁcant, whenintegrated over
the 64 combination dosing points. (A) In the replicon assay, combinations targeting sterol pathway enzymes downstream of OSC mostly appear to synergize more
toward antiviral activity, and those upstream of OSC mostly appear to show ‘epistasis,’ where the effect of modulating an upstream target dominates over those of
downstream targets at high combined concentrations. (B) Most combinations in the host toxicity assay produce responses that are close to the SPE expectation,
indicating the model represents typical levels of interaction between compounds reasonably well. Where it does occur, strong synergistic viability inhibition (S43) is
associated with compounds (e.g. clomiphene, terconazole and triparanol) that also show strong synergies outside of the sterol pathway (with TOFA and clomiphene,
or GGTI-286), and host activity within the pathway obvious mechanism-dependent patterns.
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compound’s effect. This competitive relationship between
GGTI and SQLE explains the epistatic response observed
between those two agents. For inhibitors of targets down-
stream of OSC, such as amorolﬁne, there are strong antiviral
synergies with GGTI-286. Notably, combinations with
OSC inhibitors and GGTI-286 were selective, in that compar-
able synergy was not found in the host viability assay.
Figure 4 Multi-target interactions in the replicon assay. Each panel presents a schematic of the sterol pathway showing the connection to replicon replication mediated
byproteinprenylation,alongwithresponsematricesforcombinationsrepresentingdifferentkindsofmechanisticinteractions.Dosematrices,coloredtoshowtheactivityat
each dosepoint, areshown withgreen markersindicatingthetargetsofeachcombination, andwithshape symbolsto indicate thetype ofinteraction seen(either synergy
or epistasis with an arrow indicating the direction of dominance from single agent to combination activity). (A) Combinations targeting the top of the sterol pathway
produced epistatic responses, where the upstream agent’s response predominates at high concentrations, irrespective of the pro- or antiviral activity of the single agents.
(B) Targeting the lower end of the pathway led to inhibitory synergy in both the replicon and hostviability assays, especially whenboth agents were downstream of OSC.
(C) Inhibitors of the prenylation pathway interacted weakly (close to the SPE expectation) with probes targeting enzymes at the upper end of the sterol pathway, but had
signiﬁcant interactions further downstream. The strongest synergies were produced in combination with agents targeting enzymes downstream of OSC.
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a promising avenue for future HCV therapy development.
These data further support previous ﬁndings that inhibition
of protein geranylgeranylation effectively inhibits HCV repli-
cation. We found combinations of inhibitors of the lower part
of the sterol pathway that are effective and synergistic with
each other when tested in combination. Furthermore, the
combination effects observed with simvastatin suggest that,
thoughstatinsinhibitHMGCRactivity,theresultingregulatory
consequencesof suchinhibition ultimatelyleadto undesirable
epistatic effects.
Inhibition of sterol pathway enzymes directly
impacts HMGCR protein expression and viral
RNA replication
The above results suggest that HMGCR regulation may have a
role in the epistasis of upstream sterol pathway chemical
probes over downstream probes. To determine whether our
chemical inhibitors result in an increase in HMGCR expres-
sion, we treated parental Huh-7 cells with the listed
concentrations of each chemical for 16h (Figure 5B). Cell
lysates were extracted according to the methods and HMGCR
protein expression was analyzed bySDS–PAGE separation and
western blotting with antibodies speciﬁc for HMGCR and
GAPDH. Consistent with previous studies (Stone et al, 1989;
Cohen et al, 1993), treatment of cells with simvastatin resulted
in an apparent overexpression of HMGCR. In addition,
treatment with either OSC inhibitors (U18666A or Ro48-
8071) resulted in overexpression of HMGCR, consistent with
other studies showing that treating cells with OSC inhibitors
increases HMGCRRNAlevelsandactivity(Telfordet al,2005).
Surprisingly, squalestatin also resulted in overexpression of
HMGCR, suggesting additional regulation along the pathway.
None of the other chemical probes tested produced increases
in HMGCR protein expression. Signiﬁcant reductions in
HMGCR expression were not observed, which may be
due to the half-life of the HMGCR protein, which can vary
between 410h and o20min, depending on the cell type
(Hampton, 2002).
Given the observed increases in HMGCR in response to
simvastatin, squalestatin and the OSC inhibitors, we next
soughttoevaluatetheconsequencesofsuchoverexpressionas
they pertain to HCVreplicon replication. Huh-luc/neo-ETcells
were treated with each inhibitor in Figure 5C over 72h in 96-
well plates. Total cellular RNA was extracted from the treated
cells and replicon RNA copy number in each treated
population was quantiﬁed by RT–qPCR and normalized to
total RNA. As expected, squalestatin and, to a lesser extent,
Figure 5 Validation experiments. (A) Evidence of epistasis at the level of HCV protein expression, after 96h in Huh-luc/neo-ET replicon cells, between upstream-
targeting simvastatin and downstream-targeting U18666A. Protein bands were quantiﬁed using densitometry and levels of expressed HCV proteins NS3 and NS5A are
shown as ratios normalized to GAPDH. (B) Sterol pathway regulation revealed by HMGCR protein expression in HuH-7 cells 16h after exposure to chemical inhibitors,
showing feedback effects for probes targeting the upper end of the pathway. Antibodies speciﬁc for HMGCR and GAPDH were used to probe western blots of proteins
separated by 10% Bis–Tris SDS/PAGE (see Materials and methods). (C) Conﬁrmation that agents targeting the upper and lower pathway have respectively pro- and
antiviral effects at 72h in quantitative RT–PCR experiments on Huh-luc/neo-ET cells. Averaged expression levels from triplicate experiments were calculated after
normalizing replicon copy number to total cellular RNA (see Materials and methods), and error bars show 95% conﬁdence (two standard deviations).
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observed coincident increases in HMGCR expression. In
addition,theseresultsarealsoinagreementwiththeluciferase
expression data and the viral protein expression reported
above in Figure 2, more so for squalestatin than for
simvastatin. Small increases in replicon replication observed
in both the luciferase and RT–qPCR assays were less often
visualized in western blots for replicon protein expression
(especially for simvastatin). It is possible that the greater
dynamic range afforded byqPCRaswellas the shorter half-life
ofluciferase protein inrepliconcellscontributes tosome ofthe
disparity.Counterintuitively,theobservedincreaseinHMGCR
protein expression in response to OSC inhibition did not
translate to an increase in replicon replication, but instead
inhibited HCV replicon replication. These results suggest that
there are unique consequences associated with OSC inhibition
that will require additional investigation to fully elucidate the
impact on replicon replication.
Discussion
The work reported here represents the ﬁrst large-scale
systematic chemical genetic investigation of HCV replicon
replication using a novel experimental design with both single
and combined chemical probes at multiple doses. To identify
selective antiviral effects, HCV activity and host cell viability
were monitored using cellular phenotypes that integrate the
functions of many pathways, providing insights into the
regulation and interactions between pathways. This study
extends the growing body of evidence connecting sterol
pathway metabolism to HCV replication through protein
prenylation, and identiﬁes potential therapeutic treatments
with potent and selective antiviral activity that warrantfurther
development. Despite the limitations of the cell-adapted
subgenomic replicon used in this study, the system has proven
to be predictive of drug efﬁcacy in clinical settings and we
believe it to be a reasonable predictor of mechanistic
interactions related to HCV replication. Further studies are
warranted to investigate whether the host cell interactions
observed here carry through to native HCV such as JFH1
(Wakita et al, 2005), a replication competent HCV strain.
The single-agent testing conﬁrms the connection between
sterol metabolism, protein prenylation and HCV replicon
replication. For example, the strong proviral effect of squale-
statin results from FPP being both a substrate of the sterol
pathway and an intermediate toward protein prenylation.
Farnesol, once pyrophosphorylated by the cell, is a substrate
for the synthesis of GGPP by FPP synthase. FPP is also a
substrate for the sterol pathway enzyme SQLS, which
catalyzes the synthesis of squalene. The addition of farnesol
increases both sterol synthesis and protein prenylation,
explaining the observed proviral effect. Squalestatin prevents
the further metabolism of FPP by SQLS, resulting in a buildup
of FPP and, ultimately, a shunt toward the synthesis of GGPP,
which is a substrate for geranylgeranylation of the required
host protein FBL2 (Wang et al, 2005). This proviral activity is
further accentuated by an increase in HMGCR expression seen
here and elsewhere in response to either statins (Stone et al,
1989; Cohen et al, 1993) or squalestatin.
Further downstream, the OSC inhibitors Ro48-8071 and
U18666A showed potent antiviral activity, despite the ob-
servation of a robust increase in HMGCR protein expression.
Previous studies have shown that OSC inhibitors possess a
concentration–effect relationship that is biphasic (Boogaard
et al, 1987; Cohen and Grifﬁoen, 1988; Mark et al, 1996;
Telford et al, 2005). At lower concentrations of Ro48-8071 and
U18666A, OSC is partially inhibited which favorsthe synthesis
of 24(S),25-epoxycholesterol over the synthesis of cholesterol.
24(S),25-epoxycholesterol represses HMGCR activity (Pefﬂey
et al, 1998), enhances HMGCR protein degradation (Gardner
et al, 2001) and blocks the activation of SREBP-2 (Janowski
et al, 2001), which is consistent with the observed antiviral
activity of these inhibitors at the concentrations tested in our
screen. The consequence of partial OSC inhibition ultimately
impacts intracellular GGPP levels, host protein geranylger-
anylation and replicon replication. At higher concentrations,
where OSC inhibition is complete, cholesterol synthesis is
inhibited, resultingin activation of SREBP-2 and an increasein
the expression of sterol pathway genes. This is consistent with
the observed increase in HMGCR protein expression at
concentrations in the mM range. Sterol pathway regulation,
as mediated by SREBP-2 (Horton et al, 2002), was similarly
impacted by the addition of colestolone or chemical probes
targeting lanosterol demethylase, which lead to an accumula-
tion of polar sterols (Corio-Costet et al, 1988; Schmidt et al,
2006), a down regulation of SREBP-2 activation and ultimately
to a reduction in intracellular GGPP levels, host protein
geranylgeranylation and replicon replication.
The combination effects we observed fall into consistent
patterns that support this mechanistic understanding. Gen-
erally, there was upstream epistasis for combinations between
one agent targeting the upper end of the sterolpathway (above
SQLE) and another agent targeting the lower end of the
pathway. However, for combinations inhibiting only lower
steroltargets,belowtheproteinprenylation shunt atSQLS, the
response pattern shifts predominantly toward antiviral sy-
nergy. This is especially evident downstream of OSC where
sterol metabolism becomes more complex. The cross-pathway
combinations involving the PGGT inhibitor also showed
upstream dominance for upper sterol targets. However,
combinations that inhibited both PGGT and lower sterol
targets consistently produced antiviral synergies, again espe-
cially downstream of OSC. The interaction discontinuity for
viralreplicationbetweentheupperandlowerendsofthesterol
pathway, and its absence in the host viability assay are
consistent with the existence of a prenylation shunt at SQLS
that predominantly enhances viral activity. Moreover, the
epistasis is consistent with expectations for viral activity that
does not directly affect upstream sterol metabolism, whereas
the synergy responses are consistent with expectations for a
metabolic pathway regulated by negative feedback from
downstream pathway products (Leha ´r et al, 2007). This
analysis demonstrates how a combination chemical genetic
approach can accurately reveal the critical pathway connec-
tions relevant to different biological processes.
The comparison between viral replication and host viability
also provides useful insights into potential antiviral therapies
forHCVbasedonsterolpathwayinhibition.Treatmentwithan
HMGCR inhibitor (simvastatin) increased HCV replication at
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ﬁnding that may lend some insight into recent clinical studies
of viralactivity in patients treatedwith ﬂuvastatin(Baderet al,
2008; Milazzo et al, 2009). Moreover, although HCV replica-
tion decreased under modulation of sterol-related targets such
as SREBP-2, HMGCR, OSC, C14dM (also known as CYP51A1)
or PGGT, all of the chemical probes we selected that target
these enzymes are associated with clinically relevant toxicities
that would prevent their direct translation to HCV clinical
investigations (Polak, 1992; Haria and Bryson, 1995; Swami-
nathan et al, 1995; Lobell et al, 2001; Pyrah et al, 2001;
Cenedella et al, 2004). These ﬁndings suggest that sterol
pathway inhibitors administered alone may not be effective
HCV therapeutics, given the compensatory overexpression of
HMGCR.However,targetingthesterolpathwaycanbeaviable
antiviral strategy for treating HCV, if inhibitors of the pathway
are combined. The antiviral synergies seen between the most
downstream sterol targets and also their interactions with the
prenylation pathway are generally not mirrored in the host
viability response. As with single-agent OSC inhibition, the
targeting of enzymes in the lower part of the sterol pathway
leads to the accumulation of polar sterols (Corio-Costet et al,
1988), which inhibit HMGCR enzymatic activity (Cohen and
Grifﬁoen, 1988), so it is not surprising that simultaneous
inhibitionoftheproteinprenylationandlowersterolpathways
produces synergistic antiviral effects. However, downstream
OSC inhibitors such as Ro48-8071 and U18666A have
more subtle side effects, such as the rapid induction of
cataracts and irreversible lens damage in animals (Pyrah et al,
2001; Cenedella et al, 2004) that pose serious challenges
for their therapeutic use. Limiting these associated toxicities is
a worthwhile goal for further development of inhibitors
targeting OSC.
In conclusion, this study provides a comprehensive and
unique perspective into the impact of sterol pathway regula-
tion on HCV replication and provides compelling insight into
the use of chemical combinations to maximize antiviral effects
while minimizing proviral consequences. Our results suggest
that HCV therapeutics developed against sterol pathway
targets must consider the impact on underlying sterol pathway
regulation. Inhibitors that prevent SREBP-2 activation, inhibit
PGGTor encourage the production of polar sterols have great
potential as HCV therapeutics if associated toxicities can be
reduced.
Materials and methods
Cell culture and HCV replicon
The human hepatoma cell line Huh-7 (Nakabayashi et al, 1982) and
Huh-luc/neo-ETcells (ReBLikon, GmbH) were maintained in Dulbec-
co’s modiﬁed Eagle’s medium (DMEM; Gibco, Invitrogen) supple-
mented with 10% fetal bovine serum (Gibco, Invitrogen), 1%
penicillin/streptomycin (Gibco, Invitrogen), 1% Gluta MAX-1 (Gibco,
Invitrogen) and 1% non-essential amino acids solution (Gibco,
Invitrogen) at 371C, 5% CO2. Huh-luc/neo-ET cells were grown in
medium additionally supplemented with 250mg/ml geneticin (G418,
Gibco, Invitrogen). These cells stably express an HCV genotype 1b
subgenomic replicon encoding ﬁreﬂy (Photinus pyralis) luciferase, the
coding sequence for ubiquitin and neomycin phosphotransferase
downstream of the HCV IRES and upstream of an EMCV IRES, which
mediates translation of downstream viral nonstructural proteins NS3
toNS5B (Vrolijk et al, 2003). Forall experimentalprocedures Huh-luc/
neo-ETandHuh-7parentalcellswereseededinDMEMwithoutphenol
red in the absence of G418 and penicillin/streptomycin (screening
medium).
cHTS luciferase assay and cell proliferation
inhibition assay
The cHTS procedure including plate formats is described elsewhere
(Leha ´r et al, 2009). Cells were seeded in 30ml of screening medium at
4000 cells/well on white (Huh-luc/neo-ET cells for viral inhibition
assay)orblack(Huh-7cellsforproliferationinhibitionassay)384-well
assay plates (Matrix) and incubated overnight for B20h. Using a
MiniTrak Robotic Liquid Handling System (Perkin-Elmer) 1mlo f
compound stock solutions (1000  concentration in DMSO unless
otherwise mentioned) in an X (two-fold dilutions of compound
horizontally arrayed) or Y (two-fold dilutions of compound vertically
arrayed) format was transferred from master plates into 384-well clear
bottom plates containing 100ml screening medium (dilution plates)
and mixed thoroughly. From each X and Y dilution plates, 3.3mlw a s
subsequently transferred to the 384-well assay plates for a ﬁnal
compound dilution of 1:1000 generating a 9 9 (81 point) dose–
response matrix. The cells were then incubated for 48h before
measuring luciferase activity (viral inhibition) or ATP depletion
(proliferation inhibition). In all, 25ml of SteadyLite (Perkin-Elmer)
was added to the white 384-well assay plates and 15ml of ATPLite
(Perkin-Elmer) was added to the black 384-well plates, which were
subsequently incubated at least 5min before measuring the lumine-
scent signal. All luminescence measurements were assayed for 0.1s
per well with an EnVision Xcite multilabel automatic plate reader with
Enhanced Luminescence (Perkin-Elmer) and expressed as the number
of relative light units detected. Compounds were assayed in duplicate
9 9 dose matrices on each plate and DMSO-only control wells were
included as negative untreated controls.
Immunoblot analysis
For protein expression analysis, Huh-luc/neo-ETcells were seeded in
4ml of mediumat 250000 cells per well on six-well plates and allowed
to adhere for 6–8h. Stock solutions of compound were added at a
1:1000 dilution and cells were incubated in the presence of compound
over96h. Mediumandcompounds wererefreshedonce afteran initial
incubation of 48h. Cells were washed in phosphate-buffered saline
(Gibco,Invitrogen) and lysed by the addition of 1  RIPA lysis buffer
(0.5M Tris–HCl, pH 7.4/1.5M, NaCl/2.5%, deoxycholic acid/10%,
NP-40/10mM EDTA, purchased from Upstate) containing Complete,
Mini Protease inhibitor cocktail and PhosSTOP phosphatase inhibitor
cocktailtablets (Roche)according tothe manufacturer’srecommenda-
tions. Cell lysates were rocked for 30min at 41C and centrifuged at
10000g for 10min at 41C. The protein concentration of each extract
was determined by BCA protein assay (Pierce) according to the
manufacturer’s protocol. Aliquots of extract containing 6, 8 or 10mgo f
protein were heated at 701C for 10min (excluding lysates for HMGCR
detection to minimize protein multimerization), separated by sodium
dodecyl sulfate/polyacrylamide gel electrophoresis using NuPAGE
Novex precast 10% Bis–Tris gels (Invitrogen) and transferred to
polyvinylidene diﬂuoride membranes (Invitrogen). Membranes were
blocked in 1  TBS/0.1% Tween-20 (TBS-T) containing 5% non-fat
milkbeforeprobingwiththefollowingprimaryantibodiesovernightat
41C on a rocker: mouse monoclonal anti-HCV NS5A IgG1 (1:1000,
Virogen), mouse monoclonal anti-HCV NS3 IgG (1:1000, Virogen),
mouse monoclonal anti-GAPDH (1:10000, Ambion) or mouse poly-
clonal anti-HMGCR (1:500, Novus). Membranes were washed
3 5min in TBS-T before adding a peroxidase-conjugated Immuno-
Pure rabbit anti-mouse IgG secondary antibody (Pierce) and incubat-
ing 1h at room temperature. Protein bands were visualized using the
chemiluminescence reagents SuperSignal West Femto Maximum
Sensitivity Substrate or SuperSignal West Pico Chemiluminescent
Substrate (Pierce) and an Alpha Imager digital imaging system (Alpha
Innotech).
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Measurementsof HCVRNA levels inresponse todrugwere carriedout
by ﬁrst seeding Huh-luc/neo-ETcells in 100ml of medium at 7500 cells
per well for 72h drug treatments and allowed to adhere overnight for
B20h. Compounds were added at a 1:1000 dilution in duplicate and
added to cells in three separate experiments. Total RNAwas collected
using an RNeasy 96-well kit (Qiagen) according to the manufacturer’s
protocol and quantiﬁed using the Quant-iT RiboGreen RNA Reagent
(Invitrogen). Puriﬁed RNA (4ml) was added to TaqMan reactions
containing 10ml of QuantiTect Probe RT–PCR Master Mix (Qiagen)and
0.2ml of QuantiTect RT Mix. For each HCV-speciﬁc reaction, 1.7mMo f
forward (50-CCATAGATCACTCCCCTGTG-30) and reverse (50-CCGG
TCGTCCTGGCAATTC-30) primers and 0.85mM of HCV-speciﬁc Taq-
Man probe (50-FAM-CCTGGAGGCTGCACGACACTCA-30-BHQ) were
added. All 20ml reactions were assayed in an Eppy Twin-Tec skirted
PCR plate (Eppendorf) and subjected to quantitative one-step RT–PCR
with an Eppendorf Realplex4 qPCR machine (Eppendorf) using the
following program: 501C for 30min, 951C for 15min and 40 cycles of
951Cfor15sfollowedby601Cfor1min15s.Absolutequantiﬁcationof
HCVRNAcopynumberwasdeterminedbycomparingPCRsignalstoa
standard curve generated from dilutions of a 160bp PCR-ampliﬁed
fragment of the 50NTR of HCV. The 50NTR fragment was generated by
using the HCV-speciﬁc forward and reverse primers mentioned above
and serial 10-fold dilutions were made in nuclease-free water contain-
ingyeasttRNA(25mg/ml)asacarrier.Concentrationofthe160bpHCV
standard was determined by optical density spectrophotometry at
260nm and the correspondingcopynumber was determined using the
following formula for double-stranded DNA molecules: (g of
standard 6.023 10
23 molecules/mol)/(660g/mol/base length of
ampliﬁed product in bases) (Giulietti et al, 2001; Dorak, 2006). All
qPCR samples quantiﬁed by comparison to the standard curve were
subsequently normalized to total RNA per sample to account for
variations in sample puriﬁcation and preparation steps.
Chemical reagents
Smallmoleculeenzymeinhibitorsusedinthis studywereTOFA (CAS#
54857-86-2), Colestolone (CAS# 50673-97-7), SR-12813 (CAS# 126411-
39-0), Simvastatin (CAS# 79902-63-9), Alendronate (CAS# 121268-17-
5), Farnesol (CAS# 4602-84-0), Squalestatin (CAS# 142561-96-4),
Clomiphene(CAS#50-41-9),Ro48-8071(CAS#189197-69-1),U18666A
(CAS# 3039-71-2), Terconazole (CAS# 67915-31-5), Amorolﬁne (CAS#
78613-35-1), Fenpropimorph (CAS# 67564-91-4), AY-9944 (CAS#
366-93-8), Triparanol (CAS# 78-41-1) and GGTI-286 (CAS# 171744-
11-9). DMSO was the solvent used for most chemical probes in this
study. Dithiothreitol (DTT) at 100mM in DMSO was used as a solvent
for GGTI-286 whereas ddH2O was used as a solvent for squalestatin
and U18666A.
Calculations
Dose matrices were assembled from replicate combination blocks on
experimental 384-well plates. Each plate had two replicate dose
matrices along with B20 vehicle-treated wells, and at least two copies
of each plate were obtained, resulting in 4–20 replicate matrices per
combination (Supplementary Table S1). Single-agent responses were
tested at 11 serially diluted doses and combination data as 9 9 dose
matrices each testing all pairs of 8 serially diluted single-agent
concentrations along with their single-agent doses as a control. Raw
phenotype measurements T from each treated well were converted to
normalized measures of inhibitory activity a¼ log10(T/V) or frac-
tional inhibition I¼1 T/V relative to the median V of 20 vehicle-
treated wells arranged around the plate (Leha ´r et al, 2009). The
uncertainty for each activity measurement was estimated using the
standard error sa or sI from the variance between replicates at the
same treatment doses, propagated through the activity measurement











are given in Supplementary Table S1.
The synergy for each combination was determined using a non-
standard SPE model, to properly characterize interactions between
singleagentsthatcanbothinhibitandactivaterepliconexpression.For
the SPE model, the expected activity is derived as aSPE¼max(amin,
min(amax, aminþamax)), if amin and amax are the lesser and greater
single-agent activities at the same concentrations as in a tested
combination point. SPE represents a model of expected response for
non-interacting drug targets when each drug could be either inhibitory
or stimulatory. When both drugs act in the same direction, aSPE at any
pair of concentrations is equal to the less extreme of the single drug
activities at the component concentrations. When theyact in opposing
directions(onestimulatoryandtheotherinhibitory),aSPEissimplythe
sum of the drug activities. Overall, synergy for a combination was
measured using a synergy score S¼
P
doses (adata aSPE), which is the
sum of the differences between the measured activity and the SPE
expectation, overall combined concentrations tested. Combinations
with S40 have response surfaces that are mostly more inhibited than
the SPE expectation, resulting either from synergistic activity for
inhibitory agents (both with a40), or from the inhibitor’s activity
dominating at high combined concentrations for drugs with opposing
activities. Similarly, combinations with So0 represent either antagon-
ism between inhibitory agents or dominance of the stimulatory agent.
For most of our combinations, the activity measurements at each dose
produced errors of saB0.1, so we would expect a volume calculated
across 64 combination doses to have a corresponding sSB1.6. Thus,
only scores that are 43o ro  3 can be considered signiﬁcant at the
B95% conﬁdence level.
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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